Based on the key indicators related to United Therapeutics' liquidity, profitability, solvency, and operating efficiency, United Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in March. At this time, United Therapeutics' Accounts Payable is relatively stable compared to the past year. As of 01/31/2025, Cash is likely to grow to about 1.5 B, while Non Currrent Assets Other are likely to drop slightly above 91.5 M. Key indicators impacting United Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for United Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor United Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in United Therapeutics.
United Therapeutics competes with Incyte, Alnylam Pharmaceuticals, Ultragenyx, Apellis Pharmaceuticals, and Replimune. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 965 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what United Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining United Therapeutics's current stock value. Our valuation model uses many indicators to compare United Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across United Therapeutics competition to find correlations between indicators driving United Therapeutics's intrinsic value. More Info.
United Therapeutics is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for United Therapeutics is roughly 1.58 . At this time, United Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value United Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
United Therapeutics Systematic Risk
United Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. United Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on United Therapeutics correlated with the market. If Beta is less than 0 United Therapeutics generally moves in the opposite direction as compared to the market. If United Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one United Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of United Therapeutics is generally in the same direction as the market. If Beta > 1 United Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in United Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various United Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of United Therapeutics growth as a starting point in their analysis.
United Therapeutics January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of United Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of United Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of United Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing United Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build United Therapeutics's daily price indicators and compare them against related drivers.
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.